Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application
NCT ID: NCT02280603
Last Updated: 2015-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
60 participants
INTERVENTIONAL
2014-01-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Design : Randomized, double-blind, active-controlled study
Investigational Product : Finasteride, minoxidil
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia
NCT02824380
Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss
NCT06501924
Efficacy/ Safety of DNN.22.17.036 in Male Patients With Pattern Hair Loss
NCT06355856
A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia.
NCT07011485
Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
NCT07076706
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DA-4001C
DA-4001C is administered
DA-4001C
1ml by topical application twice a day
5% minoxidil
5% minoxidil is administered
5% minoxidil
1ml by topical application twice a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DA-4001C
1ml by topical application twice a day
5% minoxidil
1ml by topical application twice a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Use of finasteride, dutasteride within previous 12 months
* Use of minoxidil within previous 6 months
* Use of androgenic or anti-androgenic agents within previous 6 months
* Use of steroid agents for local application to scalp or systemic application within previous 1 month
* History of hair transplantation, scalp reduction
* Coronary artery disease, arrhythmia, congestive heart failure, valvular haert disease, angina pectoris
18 Years
49 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dong-A ST Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hoon Kang, M.D, Ph.D
Role: PRINCIPAL_INVESTIGATOR
The catholic univ. of korea, St.Paul's hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Catholic Medical Center
Seoul, Dongdaemun-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DA4001_AGAP_POC
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.